Synta Pharmaceuticals (SNTA) gets hit hard in post-session trading after announcing mixed...

|By:, SA News Editor

Synta Pharmaceuticals (SNTA) gets hit hard in post-session trading after announcing mixed interim results from its Phase 2b study of ganetespib, a treatment for advanced non-small cell lung cancer. The company says it plans to proceed to Phase 3. Shares -17% AH.